Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | See Remarks | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 61,867 |
Ending reported balance
After 2026-02-26 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-02-26 · Exercise / conversion · Acquired 17,900 · Balance 79,767 F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Row 2 · 2026-02-26 · Sale · Disposed 17,900 · Balance 61,867 F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. F4: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Row 3 · 2026-02-26 · Exercise / conversion · Acquired 15,294 · Balance 77,161 F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Row 4 · 2026-02-26 · Sale · Disposed 15,294 · Balance 61,867 F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87 · Expires 2034-02-05 | Direct | 143,200 |
Reported balance
After 2026-02-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-26 · Exercise / conversion · Disposed 17,900 · Balance 143,200 F2: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.75 · Expires 2033-02-17 | Direct | 61,175 |
Reported balance
After 2026-02-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-26 · Exercise / conversion · Disposed 15,294 · Balance 61,175 F3: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
F2: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.
F3: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
F4: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 79,714 | $14.00 | $1,115,996.00 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 19:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 286,400 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0000950170-24-012401 · ownership.xml · derivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,400 Underlying: Ordinary Shares · 286,400 shares Expires 2034-02-05 F1 · derivative.exercise_date: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 20:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 244,700 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0000899243-23-005563 · doc4.xml · derivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,700 Underlying: Ordinary Shares · 244,700 shares Expires 2033-02-17 F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 20:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,258 | $4.03 | $41,339.74 |
DisclosureSEC source: 0000899243-23-005563 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,714 F1 · kind: On February 16, 2023, the reporting person sold 10,258 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2023. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.03 to $4.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 21:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000899243-22-026927 · doc4.xml · derivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires 2032-07-25 F1 · derivative.exercise_date: The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024. Read SEC document |
| May 05, 2022 Filed May 6, 2022 19:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,867 | $1.72 | $18,691.24 |
DisclosureSEC source: 0000899243-22-017124 · doc4.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,972 F2 · kind: On May 5, 2022, the reporting person sold 10,867 ordinary shares solely to cover taxes associated with the vesting of the PSUs on May 4, 2022. These sales were made pursuant to a provision in the reporting person's PSU agreement that requires automatic sales of shares to cover tax withholding obligations. The sales are intended to comply with Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.72 to $1.747 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2022 Filed May 6, 2022 19:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017124 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,839 F1 · kind: On March 7, 2019, the reporting person received performance-based restricted share units ("PSUs"), convertible on a one-for-one basis into ordinary shares of the issuer upon vesting. On May 4, 2022, 50% of the PSUs vested upon the issuer's achievement of the PN Chemistry Milestone (as defined in the PSU agreement) following the issuer's recent WVE-004 data release, as certified by the issuer's compensation committee. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 18:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,123 | $2.31 | $23,384.13 |
DisclosureSEC source: 0000899243-22-007065 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,339 F1 · kind: On February 16, 2022, the reporting person sold 10,123 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2022. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. F2 · price: The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $2.31 to $2.38 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 21:16 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0000899243-22-000663 · doc4.xml · derivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Ordinary Shares · 150,000 shares Expires 2032-01-01 F1 · derivative.exercise_date: The option vests as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 19:26 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,698 | $10.57 | $28,517.86 |
DisclosureSEC source: 0000899243-21-007209 · doc4.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,462 F2 · kind: On February 16, 2021, the reporting person sold 2,698 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.51 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 18, 2021 19:26 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-21-007209 · doc4.xml · derivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2031-02-01 F4 · derivative.exercise_date: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 18, 2021 19:26 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007209 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,160 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 20:42 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000899243-20-007281 · doc4.xml · derivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Ordinary Shares · 36,000 shares Expires 2030-03-03 F1 · derivative.exercise_date: The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:21 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,708 | $7.85 | $21,257.80 |
DisclosureSEC source: 0000899243-20-005346 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,160 F1 · kind: On February 18, 2020, the reporting person sold 2,708 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2020. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $7.84 to $8.147 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 19:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-007110 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,868 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 19:47 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,709 | $36.84 | $62,959.05 |
DisclosureSEC source: 0000899243-19-004460 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,368 F1 · kind: On February 19, 2019, the reporting person sold 1,709 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4713 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.1 Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 19:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 10,543 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-025322 · doc4.xml · derivative · entry 6 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,997 Underlying: Ordinary Shares · 10,543 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 19:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 10,543 | $56.00 | $590,408.00 |
DisclosureSEC source: 0000899243-18-025322 · doc4.xml · nonDerivative · entry 4 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 19:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 10,543 | $2.48 | $26,146.64 |
DisclosureSEC source: 0000899243-18-025322 · doc4.xml · nonDerivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 19:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 1,032 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-025322 · doc4.xml · derivative · entry 5 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,540 Underlying: Ordinary Shares · 1,032 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 19:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,032 | $56.00 | $57,792.00 |
DisclosureSEC source: 0000899243-18-025322 · doc4.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 19:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 1,032 | $2.48 | $2,559.36 |
DisclosureSEC source: 0000899243-18-025322 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 17:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 24,496 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-019753 · doc4.xml · derivative · entry 5 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,572 Underlying: Ordinary Shares · 24,496 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F4 · derivative.exercise_date: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 17:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 596 | $38.22 | $22,779.12 |
DisclosureSEC source: 0000899243-18-019753 · doc4.xml · nonDerivative · entry 4 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $38.10 to $38.25 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 17:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 596 | $2.48 | $1,478.08 |
DisclosureSEC source: 0000899243-18-019753 · doc4.xml · nonDerivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 17:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 23,900 | $37.25 | $890,275.00 |
DisclosureSEC source: 0000899243-18-019753 · doc4.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $37.00 to $37.975 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 17:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 23,900 | $2.48 | $59,272.00 |
DisclosureSEC source: 0000899243-18-019753 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 18:29 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 24,496 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-014735 · doc4.xml · derivative · entry 6 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,068 Underlying: Ordinary Shares · 24,496 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 18:29 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 24,496 | $48.00 | $1,175,808.00 |
DisclosureSEC source: 0000899243-18-014735 · doc4.xml · nonDerivative · entry 4 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 18:29 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 24,496 | $2.48 | $60,750.08 |
DisclosureSEC source: 0000899243-18-014735 · doc4.xml · nonDerivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 18:29 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 24,496 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-014735 · doc4.xml · derivative · entry 5 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,564 Underlying: Ordinary Shares · 24,496 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 18:29 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 24,496 | $45.50 | $1,114,568.00 |
DisclosureSEC source: 0000899243-18-014735 · doc4.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 18:29 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 24,496 | $2.48 | $60,750.08 |
DisclosureSEC source: 0000899243-18-014735 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 19:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 114 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-004954 · doc4.xml · derivative · entry 8 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,060 Underlying: Ordinary Shares · 114 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F5 · derivative.exercise_date: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 19:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 11,390 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-004954 · doc4.xml · derivative · entry 7 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,390 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F4 · derivative.exercise_date: The share option represented a right to purchase a total of 20,802 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 19:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 11,504 | $55.95 | $643,648.80 |
DisclosureSEC source: 0000899243-18-004954 · doc4.xml · nonDerivative · entry 5 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 19:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 11,504 | $2.48 | $28,529.92 |
DisclosureSEC source: 0000899243-18-004954 · doc4.xml · nonDerivative · entry 4 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 19:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 9,412 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-004954 · doc4.xml · derivative · entry 6 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,390 Underlying: Ordinary Shares · 9,412 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. F4 · derivative.exercise_date: The share option represented a right to purchase a total of 20,802 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 19:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 9,412 | $55.00 | $517,660.00 |
DisclosureSEC source: 0000899243-18-004954 · doc4.xml · nonDerivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 19:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 9,412 | $2.48 | $23,341.76 |
DisclosureSEC source: 0000899243-18-004954 · doc4.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 19:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 723 | $51.80 | $37,451.40 |
DisclosureSEC source: 0000899243-18-004954 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,077 F2 · kind: On February 16, 2018, the reporting person sold 723 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2018. These sales were made pursuant to a 10b5-1 Trading Plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $51.55 to $51.95 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002045 · doc4.xml · derivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Ordinary Shares · 26,000 shares Expires 2028-01-23 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 20:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002045 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,800 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:13 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $29.05 | $0.00 |
DisclosureSEC source: 0000899243-17-002143 · doc4.xml · derivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Ordinary Shares · 19,500 shares Expires 2027-01-25 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 15, 2021. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:13 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 9,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-002143 · doc4.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,800 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2018, through February 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.